Elecoglipron for adults with type 2 diabetes and reduced kidney function taking dapagliflozin
Tests elecoglipron against placebo in adults with type 2 diabetes and kidney problems.
Plain-language title generated from the registry record
Registry title: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
Key facts
- Where
- Chihuahua City, Cuernavaca, Guadalajara, Mexico City, Monterrey, and Zapopan, MexicoSee the 6 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes and reduced kidney function. They take other glucose-lowering medicines, with or without dapagliflozin. It compares elecoglipron with placebo.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes for at least 90 days before screening, with impaired renal function.
- Earlier treatment
- Taking other glucose-lowering medicine(s). Either on a stable dose of an SGLT2 inhibitor or never treated with one. Stable body weight for 90 days before screening.
- Biomarker or test result
- HbA1c 7.0% (53 mmol/mol) to 10.5% (53 to 91.3 mmol/mol) on a stable SGLT2 inhibitor, or 7.5% to 10.5% (58 to 91.3 mmol/mol) if never on one. BMI 23 kg/m2 or higher.
Main reasons for not taking part
- Type 1 diabetes, other forms of diabetes, or a history of ketoacidosis or hyperosmolar coma
- More than one severe low blood sugar episode in the 180 days before screening, or not noticing low blood sugar symptoms
- History of acute or chronic pancreatitis
- Severe heart failure (NYHA class IV)
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Read by machine on 9 November 2026.
Where in Mexico
- Chihuahua CityHospital not named in the registryNot yet recruiting
- CuernavacaHospital not named in the registryNot yet recruiting
- GuadalajaraHospital not named in the registryNot yet recruiting
- Mexico CityHospital not named in the registryNot yet recruiting
- MonterreyHospital not named in the registryNot yet recruiting
- ZapopanHospital not named in the registryNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07662135EU 2025-523940-12-00
- Record updated
- 2 September 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).Read full original descriptionShow less
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).
Inclusion: Diagnosed with Type 2 Diabetes Mellitus for at least 90 days prior to screening; On SGTL2i or SGLT2i-naïve and other glucose lowering medication(s); HbA1c value:; On stable dose of SGLT2i ≥ 7.0 % to ≤ 10.5% (53 to 91.3 mmol/mol); SGLT2i-naive ≥ 7.5% to ≤ 10.5% (58 to 91.3 mmol/mol); Impaired renal function; Body mass index (BMI) of ≥ 23 kg/m2 at screening; Stable body weight (self-reported or documented) for 90 days prior to screening.
Exclusion: Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms; Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; Severe congestive heart failure (New York Heart Association IV); History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.